Panama is making history in the world of medicine, and it’s about time we talk about it. The Ministry of Health has officially granted seven licenses for the sale of medicinal cannabis, marking a groundbreaking shift in the country’s approach to healthcare. But here’s where it gets even more exciting: the first pharmacy dedicated exclusively to these products has already opened its doors in Panama. This isn’t just a small step—it’s a giant leap toward providing patients with alternative treatment options that have been long awaited.
The announcement came straight from the source: Uriel Pérez, Director of Pharmacies and Drugs at the Ministry of Health, who shared the news in a recent interview on TVN. According to Pérez, one licensee took the initiative to establish a standalone pharmacy, while others will distribute medicinal cannabis products through existing pharmacies that meet the necessary regulatory standards. But here’s the part most people miss: all of this will be tightly regulated, with strict health supervision and controls in place to ensure patient safety and product quality.
To keep everything transparent, the Ministry of Health (Minsa) has launched a dedicated section on its website under the National Directorate of Pharmacies and Drugs. Here, patients and healthcare providers can find detailed information about authorized products, available batches, and the pharmacies that carry them. And this is crucial: these medications are not over-the-counter. They require a medical diagnosis, a specific prescription, and ongoing professional monitoring. No self-medication allowed—this is serious, controlled medicine.
Now, let’s break it down further. The products fall into two main categories: CBD (cannabidiol) and THC (tetrahydrocannabinol). CBD, often used for chronic pain, can be prescribed with a standard medical prescription and comes in forms like oils, creams, or tablets. THC, on the other hand, is reserved for more complex conditions like refractory epilepsy or multiple sclerosis and requires a special prescription, similar to those for controlled substances. But here’s where it gets controversial: while some see this as a progressive move, others worry about potential misuse or the challenges of regulating such potent compounds. What’s your take?
For now, all medicinal cannabis products in Panama are imported, but that’s set to change. The regulations include a two-year transition period for authorized companies to begin cultivating, processing, and manufacturing these products domestically, under the watchful eye of the Ministry of Health and with support from the Ministry of Agricultural Development. And this is the part that’s often overlooked: the technical challenges are just one piece of the puzzle. The bigger hurdle? Breaking the stigma surrounding cannabis use, even in a medical context. To tackle this, the Ministry of Health plans to roll out public awareness campaigns targeting both the general public and healthcare professionals, emphasizing the controlled, medical use of these products.
So, here’s the question: Is Panama’s move a bold step forward in healthcare, or does it open the door to potential risks? Share your thoughts in the comments—this is a conversation worth having. And if you’re curious to learn more, keep reading—this is just the beginning of a much larger story.
